article thumbnail

What recent paediatric guidelines mean for drug developers 

Drug Discovery World

Justin Hay , Senior Director, Amy Cheung Senior Director of Integrated Drug Development, and Patrick Loebs Director, at Certara, examine recent changes in paediatric guidelines and how they affect drug development projects.

article thumbnail

New anti-evolocumab antibodies could aid drug development

Drug Discovery World

These sequence-defined, recombinant antibodies are suitable for developing highly selective and sensitive pharmacokinetic (PK) and anti-drug antibody (ADA) assays for evolocumab and its biosimilars. The post New anti-evolocumab antibodies could aid drug development appeared first on Drug Discovery World (DDW).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pharmacokinetics of panobinostat: Inter-species difference in metabolic stability [Metabolism, Transport, and Pharmacogenetics]

ASPET

The objective of this study was to examine the in vitro metabolic stability of panobinostat in different matrices and assess the influence of that metabolic stability on the in vivo pharmacokinetics and CNS delivery of panobinostat.

article thumbnail

HuPK: A Humanised Platform for therapeutic antibody PK evaluation

Drug Discovery World

Download the guide to learn more about:  How JAX’s HuPK™ Humanised FcRn Platform offers a validated and cost-effective solution for assessing the in vivo  preclinical pharmacokinetics and stability of Fc-based biologics and therapeutics carried by albumin.   JAX’s portfolio of FcRn humanised mouse models. 

article thumbnail

Process Perfect Peptide Synthesis Combines Peptide and Normal Chemistry

Fierce BioTech

Join us on Monday, June 19, 2024 for one hour all about oral cyclic peptide drug development. With “specialized for peptide” drug metabolism and pharmacokinetics (DMPK) and biological evaluation, we’re able to solve certain synthesis issues found across different cyclic peptides, complexes peptides and mimetic peptides.

article thumbnail

Immunotherapy for solid tumours progresses to human trials

Drug Discovery World

Targeting EP4 to block the effects of PGE2 increases the ability of the immune system to detect and control cancer cells.

Trials 130
article thumbnail

FDA-approved drug sensitises brain cancer cells to radiotherapy

Drug Discovery World

“As an FDA-approved oral drug, the side-effects of cladribine are quite manageable and it has been well evaluated for pharmacokinetics. Additionally, the clinical trial period will be considerably shorter than that required for new drug development.